Opioids and Work Injuries -Managing Pain in the Workplace- FPM-ANZCA September 17, 2016

Transcription

1 Opioids and Work Injuries -Managing Pain in the Workplace- FPM-ANZCA September 17, 2016 Gary M. Franklin, MD, MPH Research Professor Departments of Environmental Health, Neurology, and Health Services University of Washington Medical Director Washington State Department of Labor and Industries 1

2 "To write prescriptions is easy, but to come to an understanding with people is hard." -- Franz Kafka, A Country Doctor

3 We can t solve problems by using the same kind of thinking we used when we created them

4 *Codeine, dextropropoxyphene, dihydrocodeine, fentanyl, hydromorphone, ketobemidone, morphine, oxycodone, pethidine, tilidine and trimeperidine from International Narcotics Control Board: Availability of opioids* for pain management ( average) (Consumption in defined daily doses for statistical purposes (S-DDD) per million inhabitants per day)

5 Pharmaceutical heroin

6 The worst man-made epidemic in modern medical history Over 200,000 deaths Many more hundreds of thousands of overdose admissions Millions addicted and/or dependent- lost generation Degenhardt et al Lancet Psychiatry 2015; 2: ; POINT prospective cohort: DSM-5 opioid use disorder: 29.4% Spillover effect to Federal disability programs*(franklin et al, Am J Ind Med 2015; 58: )

7 N Engl J Med. 1980;302:123.

8 Portenoy and Foley Pain 1986; 25: Retrospective case series chronic, non-cancer pain N=38; 19 Rx for at least 4 years 2/3 < 20 mg MED/day; 4> 40 mg MED/day 24/38 acceptable pain relief No gain in social function or employment could be documented Concluded: Opioid maintenance therapy can be a safe, salutary and more humane alternative

9 You will not be able to effectively alter epidemic if you don t understand how the epidemic began By the late 1990s, at least 20 states passed new laws, regulations, or policies moving from near prohibition of opioids to use without dosing guidance WA law: No disciplinary action will be taken against a practitioner based solely on the quantity and/or frequency of opioids prescribed. (WAC , 12/1999) Laws were based on weak science and good experience with cancer pain: Thus, no ceiling on dose and axiom to use more opioid if tolerance develops 9 WAC-Washington Administrative Code

10 Coronial deaths involving oxycodone and oxycodone supply, Victoria, Australia, Rintoul et al, Injury Prevention 2011; 17: 254-9

11 Unintentional Overdose Deaths Involving Opioid Analgesics Parallel Opioid Sales United States, Distribution by drug companies 96 mg/person in mg/person in 2007 Enough for every American to take 5 mg Vicodin every 4 hrs for 3 weeks Opioid sales * (mg/person) '97 '98 '99 '00 '01 '02 '03 '04 '05 '06 '07 Year 627% increase Overdose deaths 2,901 in ,499 in Opioid deaths 296% increas '99 '00 '01 '02 '03 '04 '05 '06 '07 Year 11 National Vital Statistics System, multiple cause of death data set and Drug Enforcement Administration ARCOS system; 2007 opioid sales figure is preliminary

12 Deaths Opioid-Related Deaths, Washington State Workers Compensation, Definite Probable Possible Year Franklin GM, et al, Am J Ind Med 2005;48:

13 Do function and QOL improve? Epidemiological studies are less positive, and report failure of opioids to improve QOL in chronic pain patients. Eriksen, J Pain 2006: 125: it is remarkable that opioid treatment of longterm/chronic non-cancer pain does not seem to fulfill any of the key outcome opioid treatment goals: pain relief, improved quality of life and improved functional capacity.

14 Franklin et al, Natural History of Chronic Opioid Use Among Injured Workers with Low Back Pain-Clin J Pain, Dec, /1843 (37.6%) received opioid early 111/1843 (6%) received opioids for 1 yr MED increased sign from 1st to 4th qtr Only minority improved by at least 30% in pain (26%) and function (16%) Strongest predictor of long term opioid use was MED in 1st qtr (40 mg MED had OR 6) Avg MED 42.5 mg at 1 yr; Von Korff 55 mg at 2.7 yrs

15 Evidence of effectiveness of COAT The Agency for Healthcare Research and Quality s (AHRQ) recent draft report, The Effectiveness and Risks of Long-term Opioid Treatment of Chronic Pain, which focused on studies of effectiveness measured at > 1 year of COAT use, found insufficient data on long term effectiveness to reach any conclusion, and evidence supports a dose-dependent risk for serious harms. (AHRQ 2014; Chou et al, Annals Int Med, 13 Jan 2015).

16 Enduring adaptation produced by established behaviors Addiction criteria may be different for pain patients on chronic opioids For the illicit drug user: Procurement behaviors For the pain patient much more complex: Continuous opioid therapy may prevent opioid seeking Memory of pain, pain relief and possibly also euphoria Even if the opioid seeking appears as seeking pain relief, it becomes an adaptation that is difficult to reverse It is hard to distinguish between drug seeking and relief seeking Ballantyne JC, Stannard C. New addiction criteria: Diagnostic challenges persist in treating pain with opioids. IASP: Pain clinical updates, Dec 2013; 21: 1-7; URL:

17 responding to the EVIDENCE: morphine equivalent dose RELATED RISK Risk Ratio Risk of adverse event <20 mg/day mg/day mg/day >=100 mg/day Dose in mg MED Dunn 2010 Bohnert 2011 Gomes 2011 Zedler 2014 Risk of adverse ± overdose event increases at >50 mg MED/day Risk increases greatly at 100 MED/day 2007: WA State AMDG initially recommends 120 MED threshold dose 2009: CDC recommends: 120 mg/day MED 2012: CT work comp: 90 mg/day MED 2013: OH State medical Board: 80 mg/day MED 2013: Am College Occ. & Environ Med: 50 mg/day MED 2014: CA work comp: mg/day MED Courtesy G. Franklin

18 Early opioids and disability in WA WC. Spine 2008; 33: Population-based, prospective cohort N=1843 workers with acute low back injury and at least 4 days lost time Baseline interview within 18 days(median) 14% on disability at one year Receipt of opioids for > 7 days, at least 2 Rxs, or > 150 mg MED doubled risk of 1 year disability, after adjustment for pain, function, injury severity

19 Risk/Benefit of Opioids for Chronic Non-Cancer Pain -Franklin; Neurology; Sept 2014-Position paper of the AAN-

20 Risk/Benefit of Opioids for Chronic Non-Cancer Pain -Franklin; Neurology; Sept 2014; AAN Position paper- Opioids should not be used routinely for the treatment of routine musculoskeletal conditions, headaches or fibromyalgia* *WA DLI opioid guidelines,

21 WHY NOT PRESCRIBE FOR CHRONIC LOW BACK PAIN? Alternative treatments, particularly programs that take a psycho-physical approach, have stronger evidence base 1 Opioids generally are deactivating and not activating Reduced prescribing for non-specific back pain would significantly reduce overall prescribing and availability, and thus safety public health benefit Eliminating prescribing for common indications that have failed would be a step towards identifying cases that do derive benefit Hill et al Lancet 2011;378: ; slide courtesy Jane Ballantyne, MD

22 WA State leads on reversing the epidemic 2005-Reported first deaths-franklin et al, Am J Ind Med 2005; 48: AMDG Guideline was first U.S. guideline with a dosing threshold (120 mg/day MED in 2007, updated 2010, substantial update 2015) st report of clear association of high doses with overdoses (Dunn, Von Korff et al, Ann Int Med 2010; 152: 85-92) 2010 WA legislature-repeals old, permissive rules and establishes new standards-eshb 2876-and DOH rules for all prescribers-md, DO, ARNP, DPM, DDS) 2011-UW Telepain-Dr Tauben et al

23 Washington Agency Medical Directors Opioid Dosing Guidelines Part I If patient has not had clear improvement in pain AND function at 120 mg MED (morphine equivalent dose), take a deep breath If needed, get one-time pain management consultation (certified in pain, neurology, or psychiatry) Part II Guidance for patients already on very high doses >120 mg MED 23

24 Guidance for Primary Care Providers on Safe and Effective Use of Opioids for Chronic Non-cancer Pain Establish an opioid treatment agreement Screen for Prior or current substance abuse Depression Use random urine drug screening judiciously Shows patient is taking prescribed drugs Identifies non-prescribed drugs Do not use concomitant sedative-hypnotics Track pain and function to recognize tolerance Seek help if dose reaches 120 mg MED, and pain and function have not substantially improved 24 MED, Morphine equivalent dosec

25 Open-source Tools Added to June 2010 Update of Opioid Dosing Guidelines Opioid Risk Tool: Screen for past and current substance abuse CAGE-AID screen for alcohol or drug abuse Patient Health Questionnaire-9 screen for depression 2-question tool for tracking pain and function Advice on urine drug testing CAGE, cut down annoyed guilty eye-opener 25

26 Opioid-related Death WA Workers' Compensation Opioid-related Deaths Possible Probable Definite

27 Unintentional Prescription Opioid Overdose Deaths % sustained decline Washington State Department of Health *Does not include heroin or illicit only deaths Source: Washington State Department of Health, Death Certificates

28 Agency Medical Directors Group Website

29 Slide 29

30 Slide 30

31 Garg et al, J Pain 14:

32

33 38% Increase since 2001

34 The Mercier-Franklin Opioid Boomerang, WA Workers Compensation 99% 94% 89% 84% 79% 74% 69% 64% 59% 54% Projected Percent of Loss and Percent of Claims Claims with Opioids Compared to All Claims % 19% 24% 29% Projected Percent of Claims With Opioids by Accident Quarter

35 CDC Opioid Guidelines-March 2016 Determining When to Initiate or Continue Opioids for Chronic Pain 1. Nonpharmacologic therapy and nonopioid pharmacologic therapy are preferred for chronic pain. Clinicians should consider opioid therapy only if expected benefits for both pain and function are anticipated to outweigh risks to the patient. If opioids are used, they should be combined with nonpharmacologic therapy and nonopioid pharmacologic therapy, as appropriate. 2. Before starting opioid therapy for chronic pain, clinicians should establish treatment goals with all patients, including realistic goals for pain and function, and should consider how therapy will be discontinued if benefits do not outweigh risks. Clinicians should continue opioid therapy only if there is clinically meaningful improvement in pain and function that outweighs risks to patient safety. 3. Before starting and periodically during opioid therapy, clinicians should discuss with patients known risks and realistic benefits of opioid therapy and patient and clinician responsibilities for managing therapy. Slide 35

36 CDC Opioid Guidelines-March 2016 Opioid Selection, Dosage, Duration, Follow-Up, and Discontinuation 4.When starting opioid therapy for chronic pain, clinicians should prescribe immediate-release opioids instead of extended-release/long-acting (ER/LA) opioids. 5.When opioids are started, clinicians should prescribe the lowest effective dosage. Clinicians should use caution when prescribing opioids at any dosage, should carefully reassess evidence of individual benefits and risks when increasing dosage to 50 morphine milligram equivalents (MME)/day, and should avoid increasing dosage to 90 MME/day or carefully justify a decision to titrate dosage to 90 MME/day. 6.Long-term opioid use often begins with treatment of acute pain. When opioids are used for acute pain, clinicians should prescribe the lowest effective dose of immediate-release opioids and should prescribe no greater quantity than needed for the expected duration of pain severe enough to require opioids. Three days or less will often be sufficient; more than seven days will rarely be needed. 7.Clinicians should evaluate benefits and harms with patients within 1 to 4 weeks of starting opioid therapy for chronic pain or of dose escalation. Clinicians should evaluate benefits and harms of continued therapy with patients every 3 months or more frequently. If benefits do not outweigh harms of continued opioid therapy, clinicians should optimize other therapies and work with patients to taper opioids to lower dosages or to taper and discontinue opioids. Slide 36

37 CDC Opioid Guidelines-March 2016 Assessing Risk and Addressing Harms of Opioid Use 8.Before starting and periodically during continuation of opioid therapy, clinicians should evaluate risk factors for opioid-related harms. Clinicians should incorporate into the management plan strategies to mitigate risk, including considering offering naloxone when factors that increase risk for opioid overdose, such as history of overdose, history of substance use disorder, higher opioid dosages ( 50 MME/day), or concurrent benzodiazepine use, are present. 9.Clinicians should review the patient s history of controlled substance prescriptions using state prescription drug monitoring program (PDMP) data to determine whether the patient is receiving opioid dosages or dangerous combinations that put him or her at high risk for overdose. Clinicians should review PDMP data when starting opioid therapy for chronic pain and periodically during opioid therapy for chronic pain, ranging from every prescription to every 3 months. 10.When prescribing opioids for chronic pain, clinicians should use urine drug testing before starting opioid therapy and consider urine drug testing at least annually to assess for prescribed medications as well as other controlled prescription drugs and illicit drugs. 11.Clinicians should avoid prescribing opioid pain medication and benzodiazepines concurrently whenever possible. 12.Clinicians should offer or arrange evidence-based treatment (usually medication-assisted treatment with buprenorphine or methadone in combination with behavioral therapies) for patients with opioid use disorder. Slide 37

38 WA AMDG Guideline June, 2015 Clinically Meaningful Improvement in Function Proper and Necessary Care for Opioid Prescribing Stop and Take a Deep Breath at 6 weeks and before COT Managing Surgical Pain in Workers on COT Case Definition for Discontinuing COT Addiction Treatment 38

39 When to Discontinue Opioids Patient request No CMIF as measured by validated instruments for at least 3 months during COT Risk from continued treatment outweighs benefit, including decrease in function or concomitant medications Severe adverse outcome or overdose event Non-compliance with DOH s pain management rules or AMDG Guideline Urine drug tests (UDT) results and/or patient-specific PMP data are aberrant or unexpected Drug-seeking, aberrant, or diversion behaviors pdf Slide 39

40 How to Taper Opioids Start with a taper of 10% per week. Rate depends on concurrent treatments or modalities Consider a compulsory taper (2-3 weeks) if the patient does not agree to a voluntary taper or patient with substance use disorder refuse treatment referral Prescribe clonidine for withdrawal symptoms such as restlessness, sweating, or tremor Use adjunctive therapy during taper or discontinuation (e.g. counseling, psychopharmacological support, SIMP) Do NOT reverse taper but it can be slowed. Taper needs to be unidirectional Refer patients with opioid use disorder to treatment Slide 40

41 Unintentional Opioid Overdose Deaths Washington Washington State Department of Health Source: Washington State Department of Health, Death Certificates

42 Rise in Heroin Deaths not due to Increasing Regulation Rise started well before ANY regulation Occurring in all states, most of which have done no regs Main rise in heroin deaths in year olds Main increase in prescription opioid deaths in year age groups

43 From: The Changing Face of Heroin Use in the United States: A Retrospective Analysis of the Past 50 Years JAMA Psychiatry. 2014;71(7): doi: /jamapsychiatry Figure Legend: Percentage of the Total Heroin-Dependent Sample That Used Heroin or a Prescription Opioid as Their First Opioid of AbuseData are plotted as a function of the decade in which respondents initiated their opioid abuse. Date of download: 1/18/2016 Copyright 2016 American Medical Association. All rights reserved.

44 Rate per 10,000 persons Dentists and Emergency Medicine Physicians were the main prescribers for patients 5-29 years of age 5.5 million prescriptions were prescribed to children and teens (19 years and under) in GP/FM/DO IM DENT ORTH SURG EM Age Group Source: IMS Vector One National, TPT Opioids Rate 2009

45 From: Opioid Prescribing After Surgical Extraction of Teeth in Medicaid Patients, JAMA. 2016;315(15): doi: /jama Table Title: Proportion of Medicaid Patients Dispensed Opioids Following Surgical Extraction of Teeth, a Date of download: 5/23/2016 Copyright 2016 American Medical Association. All rights reserved.

46 Opioid use for third molar extractions by oral/maxillofacial surgeons 53 third molar extractions/month 4436 practicing OMFS (80%) 2.8 million third molar extractions/year with 20 tabs hydrocodone 56 million tabs hydrocodone/year

47 Mieche et al, Pediatrics,Nov 2015: Prescription opioids in adolescence and future opioid misuse Prospective panel data from the Monitoring the Future Study N=6220 surveyed in 12 th grade and followed up through age 23 Legitimate opioid use before high school graduation is independently associated with a 33% increase in the risk of future opioid misuse after high school. This association is concentrated among individuals who have little to no history of drug use and, as well, strong disapproval of illegal drug use at baseline. Slide 47

48 Protect our children from potential abuse and addiction For teens 20 years, limit Rx s to no more than 3 days (or 10 tabs) of short acting opioids for acute, self-limited conditions Dental extractions (56 million vicodin 5 mg/year) NSAIDS/Tylenol preferred Sports injuries at ED/urgent care Could be implemented with: prior authorization only if 4 days, hard stops embedded in EMR, mandatory informed consent after 3 days This is a high road issue which would generate little pushback

49 Why consider reportability of Rx opioid overdose events LaRochelle et al, Opioid prescribing after non-fatal overdose and association with repeated overdose: A cohort study. Ann Int Med 2015; doi: /m N=2848 commercially insured patients; non-fatal overdose between May 2000-Dec 2012 Over a median follow-up of 299 days, opioids were dispensed to 91% of patients after an overdose. Seven percent of patients (n = 212) had a repeated opioid overdose. At 2 years, the cumulative incidence of repeated overdose was 17% (95% CI, 14% to 20%) for patients receiving high dosages of opioids after the index overdose, 15% (CI, 10% to 21%) for those receiving moderate dosages, 9% (CI, 6% to 14%) for those receiving low dosages, and 8% (CI, 6% to 11%) for those receiving no opioids Slide 49

50 1. Prevent future dependence, addiction and overdose among our citizens Repeal permissive 1999 model pain language Adopt and operationalize the CDC guidelines via: Setting new prescribing standards through state licensing boards Leveraging public health care purchasing programs (e.g. Medicaid) Foster strong collaboration across public program at the highest level of state government and among leaders in the medical community

51 Second key to prevention: Protect our children and teenagers For patients 20 years, limit Rx s to no more than 3 days (or 10 tabs) of short acting opioids for acute use Dental extractions (56 million Vicodin 5 mg/year) and sports injuries at emergency department/urgent care NSAIDS or Tylenol preferred Could be implemented with system changes (eg, EMR hard stops or mandatory informed consent after 3 days)

52 2. Optimize capacity to effectively treat pain and addiction Deliver coordinated, stepped care services aimed at improving pain and addiction treatment Opioid overdose case management Cognitive behavioral therapy or graded exercise to improve patient s functioning and ability to self manage their pain Medication-assisted treatment (MAT) for patients with opioid use disorder Increase access to pain and addiction experts for primary care via telepain (mentor consultation service) Incorporate these alternative treatments for pain and care coordination into payer contracts (e.g. Medicaid)

53 3. Metrics to guide both state-of-thestate and provider quality efforts Use a common set of metrics Start with public programs Establish a process for public/private implementation (e.g. WA statutory, governor appointed Bree Collaborative ) Use metrics to notify outlier prescribers

54 Rapidly increasing mortality in middle aged, lower educated whites Case and Deaton, PNAS, 2015

55 THANK YOU! For electronic copies of this presentation, please Laura Black For questions or feedback, please Gary Franklin

56 Australia mortality from prescribed opioids Opioids other than heroin comprise a larger proportion of opioid overdose deaths in 2012 compared to the 1990s Pharmaceutical opioids combined constituted the largest proportion (70%) of deaths in 2012 Although heroin deaths on their own still comprise 30% Heroin deaths are still increasing From Roxburgh, Burns, Hall, and Degenhardt, UNSW: xburgh%20-%20changing%20nature%20of%20opioid%20overdose.pdf

57 Number of opioid overdose deaths by intent and opioid type among 15 to 54 year olds, 2010 to 2012

58 Efforts in Australia to reverse epidemic and likelihood of success New, less abusable formulations +/- Electronic Recording and Reporting of Controlled Drugs system Alternative approaches to pain